2026 ACGT Investigator Award in Cell and Gene Therapy for Solid Tumor Cancers
This grant funds innovative translational research in cell and gene therapy to overcome key barriers in solid tumor cancer treatment, with a strong focus on clinical translation.
Funder: Alliance for Cancer Gene Therapy
Due Dates: May 15, 2026 (Letter of Intent) | September 1, 2026 (Full Application, by invitation)
Funding Amounts: Up to $500,000 total over 2–3 years (includes up to 10% indirect costs)
Summary: Supports innovative translational research in cell and gene therapy to overcome barriers in solid tumor cancer treatment, with an emphasis on clinical translation.
Description
This grant supports breakthrough translational research in cell and gene therapy specifically targeting solid tumor cancers. The program seeks proposals that address the unique challenges of solid tumors—such as antigen heterogeneity, immunosuppressive microenvironments, and safety limitations—by integrating innovative strategies with strong mechanistic rationale and clear clinical translation potential. Eligible research approaches include engineered T cell therapies (e.g., CAR-T, TCR-T), innate and alternative immune cell platforms, gene editing and synthetic biology, microenvironment-modulating interventions, and rational combinatorial regimens. Projects that combine multiple approaches to overcome trafficking, suppression, antigen escape, and safety barriers are strongly encouraged.
